Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BPX-701 |
Trade Name | |
Synonyms | |
Drug Descriptions |
BPX-701 is an autologous T-cell therapy that targets HLA-A201, PRAME (preferentially-expressed antigen in melanoma), and contains a drug binding domain for caspase 9 (CASP9) initiation, thereby potentially inducing cell death (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C128029 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BPX-701 | BPX-701 | 0 | 1 |
BPX-701 + Rimiducid | BPX-701 Rimiducid | 0 | 0 |